These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2243148)

  • 1. Antihypertensive effects of a new sustained-release formulation of nifedipine.
    Zachariah PK; Schwartz GL; Sheps SG; Schirger A; Carlson CA; Moore AG
    J Clin Pharmacol; 1990 Nov; 30(11):1012-9. PubMed ID: 2243148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, controlled, multicenter, randomized study comparing the antihypertensive effectiveness and tolerance of a daily dose of two nifedipine formulations: nifedipine microgranules versus nifedipine osmotic pump.
    de Roa ER; Botero R; Octavio JA; Berrizbeitia ML; Mayorca E; Castro P; Miranda R; Valecillo E; Aroca G; Aza G; González M
    Am J Ther; 2007; 14(2):140-6. PubMed ID: 17414581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of once-daily nifedipine administered without food: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate hypertension. Nifedipine Study Group.
    Glasser SP; Ripa SR; Allenby KS; Schwartz LA; Commins BM; Jungerwirth S
    Clin Ther; 1995; 17(2):296-312. PubMed ID: 7614530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood pressure control in patients with mild to moderate essential hypertension switched from nifedipine gastrointestinal therapeutic system (GITS) 30 mg to nifedipine GITS 20 mg.
    Toal CB;
    Clin Ther; 2001 Jan; 23(1):87-96. PubMed ID: 11219482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nifedipine gastrointestinal therapeutic system versus nifedipine coat-core: comparison of efficacy via 24-hour ambulatory blood pressure monitoring.
    Defina LF; Bookstaver DA; Goldfinger MP; Coffey TA
    Ann Pharmacother; 1997; 31(7-8):819-22. PubMed ID: 9220037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium antagonist.
    Carr AA; Bottini PB; Feig P; Prisant LM; Mulligan S; Devane JG; Fisher L; Rhoades RB; MacCarthy EP
    Am J Cardiol; 1992 Apr; 69(13):28E-32E. PubMed ID: 1575174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product.
    White WB; Black HR; Weber MA; Elliott WJ; Bryzinski B; Fakouhi TD
    Am J Cardiol; 1998 Feb; 81(4):424-31. PubMed ID: 9485131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 24-hour efficacy of a new once-daily formulation of nifedipine. Italian Nifedipine GITS Study Group.
    Zanchetti A
    Drugs; 1994; 48 Suppl 1():23-30; discussion 30-1. PubMed ID: 7533703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension.
    Juttmann JR; de Vries Robles P; Venuti RP
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S134-7. PubMed ID: 1378141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-four-hour blood pressure monitoring during treatment with extended-release felodipine versus slow-release nifedipine in elderly patients with mild to moderate hypertension: a randomized, double-blind, cross-over study.
    Bonaduce D; Canonico V; Petretta M; Forgione L; Ianniciello A; Cavallaro V; Bertocchi F; Rengo F
    Eur J Clin Pharmacol; 1997; 53(2):95-100. PubMed ID: 9403278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension.
    Fagan TC; Haggert BE; Liss C
    Clin Ther; 1994; 16(4):634-46. PubMed ID: 7982251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive efficacy of a slow release nifedipine tablet formulation given once daily in patients with mild to moderate hypertension. A placebo-controlled, double-blind parallel-group trial.
    Harder S; Rietbrock S; Thürmann P
    Arzneimittelforschung; 1994 Feb; 44(2):133-6. PubMed ID: 8147945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins.
    Lacourcière Y; Poirier L; Lefebvre J; Provencher P; Arnott W
    J Clin Pharmacol; 1992 Jul; 32(7):660-6. PubMed ID: 1353507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ambulatory blood pressure profiles in essential hypertensives after treatment with a new once daily nifedipine formulation.
    Nold G; Herholz C; Sturm M; Hopf R; Lemmer B
    J Hum Hypertens; 1999 Mar; 13(3):173-7. PubMed ID: 10204813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of amlodipine and the nifedipine retard preparation in the treatment of arterial hypertension].
    Pivac N; Dobovisek J; Bagatin J; Gros Furek V; Rumboldt Z; Janezić A; Kveder R; Sjerobabski V; Simunić M; Sardelić S
    Lijec Vjesn; 1993; 115(11-12):356-9. PubMed ID: 8176999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trough and peak effects of a single daily dose of nifedipine gastrointestinal therapeutic system (GITS) as assessed by ambulatory blood pressure monitoring. Italian Nifedipine GITS Study Group.
    Zanchetti A
    J Hypertens Suppl; 1994 Jul; 12(5):S23-7. PubMed ID: 7965282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of felodipine and nifedipine on 24-h blood pressure and left ventricular mass.
    Myers MG; Leenen FH; Tanner J
    Am J Hypertens; 1995 Jul; 8(7):712-8. PubMed ID: 7546497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-over comparison of nifedipine Oros and felodipine extended release with blind 24 h ambulatory blood pressure assessments.
    Taverner D; Marley J; Tonkin AL
    Clin Exp Pharmacol Physiol; 1999 Nov; 26(11):909-13. PubMed ID: 10561813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of once-daily nifedipine: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate diastolic hypertension. Nifedipine Study Group.
    Glasser SP; Jain A; Allenby KS; Shannon T; Pride K; Pettis PP; Schwartz LA; MacCarthy EP
    Clin Ther; 1995; 17(1):12-29. PubMed ID: 7758054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective controlled trial of two nifedipine extended release formulations in the treatment of essential hypertension.
    Pivac N; Naranca M; Vujic-Podlipec D; Bagatin J; Rumboldt Z
    Arzneimittelforschung; 2002; 52(5):379-84. PubMed ID: 12087923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.